Clinical trial
REduced Frequency ImmuNE Checkpoint Inhibition in Cancers
NCT04913025 · University College, London, Other · Unknown status
Key facts
| NCT number | NCT04913025 |
|---|---|
| Title | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers |
| Official title | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers: A Multi Arm Phase II Basket Protocol Testing Reduced Intensity Immunotherapy Across Different Cancers |
| Acronym | REFINE |
| Lead sponsor | University College, London, Other |
| Collaborators | JP Moulton Charitable Foundation |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma, Melanoma |
| Intervention type | Drug |
| Interventions | Nivolumab, Pembrolizumab |
| Enrollment | 160 |
| Start date | May 26, 2022 |
| Primary completion | Apr 1, 2025 |
| Completion | Apr 1, 2025 |
| First posted | Jun 4, 2021 |
| Last update posted | Sep 21, 2022 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: